Global experts in diagnostic medicine, medical physics and image analysis

Clinical Trials

LiverMultiScan measures response to treatment

LiverMultiScan is suitable for monitoring effects during interventional trials.

We have developed a dedicated research service, LiverMultiScan Discover, in response to the enhanced requirements of our research partners, including volumetric burden of disease.

LiverMultiScan Discover currently supports a number of clinical and preclinical trials for drugs under assessment for treatment of non-alcoholic fatty liver disease – NAFLD – and non-alcoholic steatohepatitis (NASH), including Galectin’s Phase 2 GR-MD-02 trial.

Contact us today to see how LiverMultiScan can make the difference in your clinical trial.

Clinical Pathway

 

 

 

 

 

LiverMultiScan is unique in that it was designed by a team of physicians and scientists in collaboration, and so has been optimized for general clinical use from the outset. It is generalizable, and completely safe.

Contact us today to learn more about early efficacy signals, surrogate endpoints and screening and enrichment for optimization of patient cohorts in clinical trials.


This is the first demonstration of a non-invasive test to differentiate early stages of fibrosis from normal liver.



'As a truly non-invasive technique for the characterisation of liver tissue, this methodology has the potential for the safe longitudinal assessment and prediction of disease progression and regression and/or response to therapy, without the need for repeat liver biopsy.' (Journal of Hepatology 2014;60, 69-77)